Xoma Completes Acquisition of Lava Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 21 2025
0mins
Acquisition Details: XOMA Royalty has completed the acquisition of all outstanding shares of LAVA Therapeutics, with shareholders receiving $1.04 in cash per share and a contingent value right for additional payments based on future proceeds.
Shareholder Participation: A total of 23,956,708 shares, representing approximately 91.1% of outstanding shares, were tendered in the acquisition, leading to a corporate reorganization.
Post-Acquisition Actions: Following the acquisition, LAVA will undergo a corporate reorganization, and all remaining shareholders will receive the same cash and contingent value right as those in the tender offer.
Trading Suspension: Public trading of LAVA shares was suspended prior to November 21, 2025, with plans for delisting from Nasdaq and deregistration under the Securities Exchange Act.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XOMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XOMA
Wall Street analysts forecast XOMA stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 41.720
Low
50.00
Averages
71.00
High
97.00
Current: 41.720
Low
50.00
Averages
71.00
High
97.00
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
XOMA Announces Cash Dividends and Redemption Plan
- Cash Dividend Announcement: XOMA's Board has authorized cash dividends for holders of 8.625% Series A and 8.375% Series B Preferred Stock, with A shares receiving $0.53906 and B shares $0.52344, reflecting the company's commitment to shareholder returns.
- Redemption Plan: All outstanding Preferred Stock will be redeemed on July 14, 2026, at a price of $25.00 per share, which is expected to impact the company's capital structure and reduce future dividend expenditures.
- Merger Progress: The redemption is linked to the pending merger with Flex Merger Sub, Inc., indicating that the company is actively pursuing strategic integration that may enhance its competitive position in the market.
- Additional Rights Distribution: XOMA will also distribute contingent value rights to common stockholders on July 13, 2026, further enhancing shareholder value and demonstrating strategic considerations in the merger process.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Targeted Companies: Halper Sadeh LLC is investigating Avanos Medical, Inc., Nuvalent, Inc., XOMA Royalty Corporation, and TruBridge, Inc. for potential violations of federal securities laws or breaches of fiduciary duties, including Avanos's sale to American Industrial Partners for $25.00 per share.
- Shareholder Rights: Shareholders are encouraged to contact Halper Sadeh LLC to discuss their rights and options, with the firm offering to handle matters on a contingent fee basis, emphasizing its commitment to protecting shareholder interests.
- Potential Benefits: The investigation may lead to increased consideration or additional disclosures for shareholders, indicating Halper Sadeh LLC's dedication to securing better financial outcomes and transparency for investors.
- Legal Advocacy: Halper Sadeh LLC represents investors globally, focusing on securities fraud and corporate misconduct cases, having successfully recovered millions for defrauded investors, showcasing its expertise in safeguarding investor rights.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the acquisition of Taylor Morrison Home Corp. by Berkshire Hathaway, with shareholders expected to receive $72.50 per share in cash, potentially providing significant financial returns for investors.
- Caesars Entertainment Transaction: In the deal with Fertitta Gaming Holdco, Caesars shareholders are anticipated to receive $31.00 per share in cash along with a ticking consideration, which could enhance shareholder returns over time.
- XOMA Shareholder Gains: XOMA Royalty Corporation's sale to Ligand Pharmaceuticals will see shareholders receiving $39.00 per share in cash, offering a clear and immediate financial benefit to investors.
- Avanos Medical Acquisition: Avanos Medical, Inc. is set to provide shareholders with $25.00 per share in cash from its sale to American Industrial Partners, with a shareholder vote scheduled for July 22, 2026, to finalize the transaction.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Caesars Entertainment, Inc. (NASDAQ: CZR) for its sale to Fertitta Entertainment, Inc. at $31.00 per share in cash, potentially violating fiduciary duties and impacting shareholder rights.
- Potential Violations: The sale of XOMA Royalty Corporation (NASDAQ: XOMA) to Ligand Pharmaceuticals Incorporated for $39.00 per share is also under scrutiny, as it may limit superior competing offers, thereby harming shareholder interests.
- Legal Rights: LiveRamp Holdings, Inc. (NYSE: RAMP) is being sold to Publicis Groupe for $38.50 per share, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and options to ensure their interests are protected.
- Shareholder Protection: The transaction involving Taylor Morrison Home Corporation (NYSE: TMHC) selling to Berkshire Hathaway Inc. for $72.50 per common share in cash may lead Halper Sadeh LLC to seek increased compensation and additional disclosures to safeguard shareholder rights.
See More
XOMA (XOMA) Q4 2025 Earnings Call Transcript
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, Organon & Co., and Veris Residential, Inc. for potential violations of federal securities laws and breaches of fiduciary duties to shareholders, with transaction prices at $39.00, $14.00, and $19.00 per share respectively, indicating potential threats to shareholder rights.
- Shareholder Rights Protection: The law firm encourages shareholders to contact them to discuss their rights and options, promising to provide legal services on a contingency fee basis, aiming to secure higher transaction prices and additional disclosures for affected investors, thereby enhancing legal protections for shareholders.
- Potential Impact: The investigation may lead to a reassessment of transaction terms, particularly those that could limit superior competing offers, and if successful, could yield greater financial benefits for shareholders, reflecting a commitment to corporate governance and transparency.
- Legal Service Commitment: Halper Sadeh LLC states it will represent investors globally in seeking legal remedies, having previously recovered millions for victims of securities fraud, showcasing its expertise and influence in addressing corporate misconduct.
See More
XOMA Announces Cash Dividends and Redemption Plan
- Cash Dividend Announcement: XOMA's Board has authorized cash dividends for holders of 8.625% Series A and 8.375% Series B Preferred Stock, with A shares receiving $0.53906 and B shares $0.52344, reflecting the company's commitment to shareholder returns.
- Redemption Plan: All outstanding Preferred Stock will be redeemed on July 14, 2026, at a price of $25.00 per share, which is expected to impact the company's capital structure and reduce future dividend expenditures.
- Merger Progress: The redemption is linked to the pending merger with Flex Merger Sub, Inc., indicating that the company is actively pursuing strategic integration that may enhance its competitive position in the market.
- Additional Rights Distribution: XOMA will also distribute contingent value rights to common stockholders on July 13, 2026, further enhancing shareholder value and demonstrating strategic considerations in the merger process.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Targeted Companies: Halper Sadeh LLC is investigating Avanos Medical, Inc., Nuvalent, Inc., XOMA Royalty Corporation, and TruBridge, Inc. for potential violations of federal securities laws or breaches of fiduciary duties, including Avanos's sale to American Industrial Partners for $25.00 per share.
- Shareholder Rights: Shareholders are encouraged to contact Halper Sadeh LLC to discuss their rights and options, with the firm offering to handle matters on a contingent fee basis, emphasizing its commitment to protecting shareholder interests.
- Potential Benefits: The investigation may lead to increased consideration or additional disclosures for shareholders, indicating Halper Sadeh LLC's dedication to securing better financial outcomes and transparency for investors.
- Legal Advocacy: Halper Sadeh LLC represents investors globally, focusing on securities fraud and corporate misconduct cases, having successfully recovered millions for defrauded investors, showcasing its expertise in safeguarding investor rights.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the acquisition of Taylor Morrison Home Corp. by Berkshire Hathaway, with shareholders expected to receive $72.50 per share in cash, potentially providing significant financial returns for investors.
- Caesars Entertainment Transaction: In the deal with Fertitta Gaming Holdco, Caesars shareholders are anticipated to receive $31.00 per share in cash along with a ticking consideration, which could enhance shareholder returns over time.
- XOMA Shareholder Gains: XOMA Royalty Corporation's sale to Ligand Pharmaceuticals will see shareholders receiving $39.00 per share in cash, offering a clear and immediate financial benefit to investors.
- Avanos Medical Acquisition: Avanos Medical, Inc. is set to provide shareholders with $25.00 per share in cash from its sale to American Industrial Partners, with a shareholder vote scheduled for July 22, 2026, to finalize the transaction.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Caesars Entertainment, Inc. (NASDAQ: CZR) for its sale to Fertitta Entertainment, Inc. at $31.00 per share in cash, potentially violating fiduciary duties and impacting shareholder rights.
- Potential Violations: The sale of XOMA Royalty Corporation (NASDAQ: XOMA) to Ligand Pharmaceuticals Incorporated for $39.00 per share is also under scrutiny, as it may limit superior competing offers, thereby harming shareholder interests.
- Legal Rights: LiveRamp Holdings, Inc. (NYSE: RAMP) is being sold to Publicis Groupe for $38.50 per share, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and options to ensure their interests are protected.
- Shareholder Protection: The transaction involving Taylor Morrison Home Corporation (NYSE: TMHC) selling to Berkshire Hathaway Inc. for $72.50 per common share in cash may lead Halper Sadeh LLC to seek increased compensation and additional disclosures to safeguard shareholder rights.
See More
XOMA (XOMA) Q4 2025 Earnings Call Transcript
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, Organon & Co., and Veris Residential, Inc. for potential violations of federal securities laws and breaches of fiduciary duties to shareholders, with transaction prices at $39.00, $14.00, and $19.00 per share respectively, indicating potential threats to shareholder rights.
- Shareholder Rights Protection: The law firm encourages shareholders to contact them to discuss their rights and options, promising to provide legal services on a contingency fee basis, aiming to secure higher transaction prices and additional disclosures for affected investors, thereby enhancing legal protections for shareholders.
- Potential Impact: The investigation may lead to a reassessment of transaction terms, particularly those that could limit superior competing offers, and if successful, could yield greater financial benefits for shareholders, reflecting a commitment to corporate governance and transparency.
- Legal Service Commitment: Halper Sadeh LLC states it will represent investors globally in seeking legal remedies, having previously recovered millions for victims of securities fraud, showcasing its expertise and influence in addressing corporate misconduct.
See More
